Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep 15;9(9):341-353.
doi: 10.4251/wjgo.v9.i9.341.

Epigenetics of gastroenteropancreatic neuroendocrine tumors: A clinicopathologic perspective

Brendan M Finnerty  1 , Katherine D Gray  2 , Maureen D Moore  2 , Rasa Zarnegar  2 , Thomas J Fahey Iii  2
Affiliations
Review

Epigenetics of gastroenteropancreatic neuroendocrine tumors: A clinicopathologic perspective

Brendan M Finnerty et al. World J Gastrointest Oncol. .

Abstract

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of rare tumors whose site-specific tumor incidence and clinical behavior vary widely. Genetic alterations associated with familial inherited syndromes have been well defined; however, the genetic profile of sporadic tumors is less clear as their tumorigenesis does not appear to be controlled by classic oncogenes such as P53, RB, or KRAS. Even within GEP-NETs, there are no common oncogenic drivers; for example, DAXX/ATRX mutations are strongly implicated in the tumorigenesis of pancreatic but not small bowel NETs. Accordingly, the dysregulation of epigenetic mechanisms has been hypothesized as a potential regulator of GEP-NET tumorigenesis and has become a major focus of recent studies. Despite the heterogeneity of tumor cohorts evaluated in these studies, it is obvious that there are methylation patterns, chromatin remodeling alterations, and microRNA and long non-coding RNA (lncRNA) differential expression profiles that are distinctive of GEP-NETs, some of which are correlated with significant differences in clinical outcomes. Several translational studies have provided convincing data identifying potential prognostic biomarkers, and some of these have demonstrated preliminary success as serum biomarkers that can be used clinically. Nevertheless, there are many opportunities to further define the mechanisms by which these epigenetic modifications influence tumorigenesis, and this will provide better insight into their prognostic and therapeutic utility. Furthermore, these findings form the foundation for future studies evaluating the clinical efficacy of epigenetic modifications as prognostic biomarkers, as well as potential therapeutic targets.

Keywords: Carcinoid; Chromatin remodeling; Epigenetics; Histone modifications; LncRNA; Methylation; MicroRNA; Neuroendocrine.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: There are no conflicts of interest to report.

Figures

Figure 1
Figure 1
MicroRNA in neuroendocrine tumors. PNET: Pancreatic tumors; SB-NETs: Small bowe neuroendocrine tumors.
See this image and copyright information in PMC

References

    1. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40:1–18, vii. - PubMed
    1. Öberg K. The genetics of neuroendocrine tumors. Semin Oncol. 2013;40:37–44. - PubMed
    1. Williams GT. Endocrine tumours of the gastrointestinal tract-selected topics. Histopathology. 2007;50:30–41. - PubMed
    1. Yoshimoto K, Iwahana H, Fukuda A, Sano T, Saito S, Itakura M. Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Cancer Res. 1992;52:5061–5064. - PubMed
    1. Chung DC, Smith AP, Louis DN, Graeme-Cook F, Warshaw AL, Arnold A. Analysis of the retinoblastoma tumour suppressor gene in pancreatic endocrine tumours. Clin Endocrinol (Oxf) 1997;47:523–528. - PubMed